WASHINGTON (AP) - Federal prosecutors allege that Indian generic
drugmaker Ranbaxy Laboratories deliberately misled the U.S.
government about the quality of its low-cost medicines.
The Justice Department is demanding Ranbaxy turn over documents
which it hopes will prove the company fabricated data to convince
the U.S. government to approve its products.
Prosecutors made the allegations in a motion filed July 3 with
the U.S. District Court of Maryland. The filing asks the court to